Cyplasin Biomedical (CPBM.OB) Provides Corporate Update on 2010 Operations, Projects 2011 Strategy
Cyplasin Biomedical, www.c-pharma.net – the Alberta-based pharmaceutical developer which has assembled quite a portfolio in the HCV infection (hepatitis C) space, including HCV vaccines based on recombinant DNA technology and generic HCV-therapeutic drugs, took some time today to provide an update on 2010 operations. CEO of CPBM, Garth Likes, commended his colleagues for their exemplary work in overcoming the many challenges the Company had to face in 2010, expressing strong assurances that the year was a “foundation building year” for CPBM and that the Company is well positioned to execute on its 2011 strategy. Likes cited key elements of the…